Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

doi:10.1016/j.ejca.2017.12.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2018

Verlingue Loic, Hollebecque Antoine, Lacroix Ludovic, Postel-Vinay Sophie, Varga Andrea, El Dakdouki Yolla, Baldini Capucine, Balheda Rastilav, Gazzah Anas, Michot Jean-Marie, Marabelle Aurélien, Mir Olivier, Arnedos Monica, Rouleau Etienne, Solary Eric, De Baere Thierry, Angevin Eric, Armand Jean-Pierre, Michiels Stefan, André Fabrice, Deutsch Eric, Scoazec Jean-Yves, Soria Jean-Charles, Massard Christophe

Abstract excerpt

INTRODUCTION: Therapeutic inhibition of the human epidermal receptor 3 (ERBB3, HER3) has been challenged by the low frequency of ERBB3 somatic alterations across cancer types. We have evaluated the clinical utility to use available inhibitors of the HER family in the context of ERBB3 mutations. PATIENTS AND METHODS: In this study, we have selected patients with somatic ERBB3 alterations detected in their tumours...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Comparative Genomic Hybridization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Exome Sequencing

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Share to Receptor, ErbB-3

Source

Open in PubMed

Identifiers

PMID: 29413684
DOI: 10.1016/j.ejca.2017.12.020

Genes

ERBB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.PMID 29413684Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Oncogenic ERBB3 mutations in human cancers.Semantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

HER family in cancer progression: From discovery to 2020 and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.